BioStock: Coegin Pharma fuses with Swedish biotech Follicum

Soon after receiving the green light from the Danish Medicines Agency for initiating the phase I/II COAK study in actinic keratosis, Nordic biotech Coegin Pharma reveals new plans for growth and expansion through a merger with Swedish biotech Follicum. BioStock spoke with Coegin’s CEO Tore Duvold to learn the details of the merger and the future implications for the company.

Read the interview with Tore Duvold at biostock.se:

https://www.biostock.se/en/2021/09/coegin-pharma-fuses-with-swedish-biotech-follicum/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/